External broker reports(aggregated public sources), Taylor Collison

Taylor Collison

Taylor Collison is a leading financial services firm, providing advice & wealth creation strategies to private & institutional investors and corporate clients throughout Australia. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<ul>
<li>PXS reported encouraging proof of concept data last month for its PXS-6302 skin scar treatment.</li>
<li>PXS-6302 reduced the excess collagen content in established scars by up to 50%.</li>
<li>While there was no overall improvement in scar appearance, this was not surprising given the average age of the scars treated (~13 years) and the short duration of treatment.</li>
</ul>
<p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>


PXS reported encouraging proof of concept data last month for its PXS-6302 skin scar treatment.
PXS-6302 reduced the excess collagen content in established scars by up to 50%.
While there was no overall improvement in scar appearance, this was not surprising given the average age of the scars treated (~13 years) and the short duration of treatment.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pharmaxis (PXS) - Progressing to Next Stage in Scarring and Myelofibrosis

Syntara

Pharmaxis (PXS) - Progressing to Next Stage in Scarring and Myelofibrosis